Drug intelligence / Profile preview

Exib

Development stage: Unknown
Lead developer: Darnitsa
Modality: Small Molecules
Administration: Oral

Overview

Exib is a selective cyclooxygenase-2 (COX-2) inhibitor developed by Darnitsa Pharmaceutical Company. As a nonsteroidal anti-inflammatory drug (NSAID), it is used for the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. It is a small molecule drug formulated as film-coated tablets. In clinical development, it demonstrated bioequivalence to the reference product Arcoxia, confirming its efficacy and safety profile for pain management and antirheumatic therapy.

Brand names: Exib
Other names: etoricoxib

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Exib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exib.

Explore the full profile